MetaVia Inc. Common Stock (MTVA)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At $1.43 on 2026-10-13, MetaVia has a market capitalization of only $9.4 million. This is a clinical-stage biotechnology company with no revenue in any period shown and net losses in fiscal 2023, fiscal 2024, fiscal 2025, and the quarter ended 2026-06-30. The reported losses were $12.5 million, $27.6 million, $13.0 million, and $5.3 million, respectively. The most recent diluted EPS was -$0.90. FairStock's trailing P/E is -0.58, and EPS is -$2.45; those negative numbers simply confirm there are no earnings to value. FairStock's P/B is 1.37, but ROE is -175.68% and ROCE is -58.82%, so capital is being consumed, not compounded. Debt is low at D/E 0.03, which helps, but trailing free cash flow is -$15.8 million and FCF yield is -168.1%, meaning the cash burn exceeds the entire market value. Piotroski is 2/9 and Altman is -15.18, both pointing to financial weakness. The business has two clinical programs, DA-1241 in Phase 2a for MASH and DA-1726 in development, but with eight employees and no sales, the moat, if any, is unproven science and intellectual property. Peter Lynch would have no category because losses persist. FairStock Score is 68/100, but that does not make this a Graham bargain: asset value is modest, earnings are negative, and future value depends on trial outcomes. This is speculation on clinical data and financing, not a predictable value compounder.

In plain English: MetaVia is a very small company that is testing new medicines for heart and metabolic diseases. It has no product sales yet and has lost money for years, including $5.3 million in the quarter ended June 30, 2026, while burning cash faster than its $9.4 million market value. At $1.43 on 2026-10-13, the stock looks speculative rather than clearly cheap on its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer